Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) LT-Debt-to-Total-Asset : 1.35 (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Parnell Pharmaceuticals Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2018 was 1.35.

Parnell Pharmaceuticals Holdings's long-term debt to total assets ratio increased from Dec. 2016 (0.63) to Dec. 2018 (1.35). It may suggest that Parnell Pharmaceuticals Holdings is progressively becoming more dependent on debt to grow their business.

Parnell Pharmaceuticals Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings LT-Debt-to-Total-Asset Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.63

1.07

1.35

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			-	0.31	0.63	1.07	1.35

Parnell Pharmaceuticals Holdings LT-Debt-to-Total-Asset Calculation

Parnell Pharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )	/	Total Assets (A: Dec. 2018 )
	=	32.282	/	24.003
	=	1.34

Parnell Pharmaceuticals Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (Q: Dec. 2018 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2018 )	/	Total Assets (Q: Dec. 2018 )
	=	32.282	/	24.003
	=	1.34

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Parnell Pharmaceuticals Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.